Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, from Sarah Cannon Research Institute UK, London, UK, discusses an open-label, biomarker-directed, multi-drug, multi-center, multi-arm, randomized phase 1b clinical trial in patients with muscle-invasive urothelial carcinoma of the bladder who have progressed on prior treatment.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.